Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05471271
Other study ID # 202100912
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date November 2026

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact Elisabeth de Vries, MD/PhD
Phone +31503616161
Email e.g.e.de.vries@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer [18F]AlF-RESCA-IL2 in patients prior to and during treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 14
Est. completion date November 2026
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years at the time of signing informed consent. 2. Patients with histologically confirmed diagnosis of locally advanced or metastatic solid cancer, eligible for ICI therapy as part of routine care. 3. At least 1 lesion that is accessible per investigator's assessment and eligible for biopsy according to standard clinical care procedures. 4. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions except for lesions that have progressed after radiotherapy. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy = 12 weeks. 7. Signed informed consent. 8. Willingness and ability to comply with all protocol required procedures. 9. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate (< 1% per year) when used consistently and correctly)). Exclusion Criteria: 1. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to [18F]AlF-RESCA-IL2 injection. 2. Evidence of an active infection that requires systemic antibiotics within 2 weeks prior to [18F]AlF-RESCA-IL2 injection. 3. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of [18F]AlF-RESCA-IL2, or that may affect the interpretation of the results or render the patient at high risk from complications. 4. Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. 5. Sponsor employee/member of the clinical site study team and/or his or her immediate family 6. Pregnant or lactating females. 7. Concurrent use of systemic corticosteroids > 10 mg daily prednisone equivalent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
[18F]AlF-RESCA-IL2 PET scan
Patients will undergo [18F]AlF-RESCA-IL2 PET imaging twice; the first [18F]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second [18F]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events related to [18F]-AlF-RESCA-IL2 administration as assessed by CTCAE v5.0 Safety assessment through summaries of adverse events, changes in laboratory test results (if evaluation is indicated) and changes in vital signs. Adverse event data will be recorded and summarized according to NCI CTCAE v5.0 2 years
Primary Non-displaceable binding potential (BPND) To evaluate the pharmacokinetic behaviour of 18F-AIF-RESCA-IL2 through activity in venous blood samples, dynamic imaging, and pharmacokinetic modeling. 2 years
Primary Total volume of distribution (VT) of the tracer in the tumour To evaluate the pharmacokinetic behaviour of 18F-AIF-RESCA-IL2 through activity in venous blood samples, dynamic imaging, and pharmacokinetic modeling. 2 years
Primary Biodistribution of [18F]-AlF-RESCA-IL2 Evaluation of [18F]AlF-RESCA-IL2 biodistribution in cancer patients on the PET images by measuring standardized uptake values in tumours, healthy tissues and organs. 2 years
Secondary Correlation of 18F-AlF-RESCA-IL2 uptake in tumours, with T cell infiltration in tumour biopsy samples, as determined by IHC. Results of immunohistochemical (IHC) scoring of immune cell IL-2R expression will be described as a semi-quantitative score using the percentage of positive cells (continuous variable), intensity and pattern of staining (discrete variable). These IHC results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images. 2 years
Secondary Correlation of 18F-AlF-RESCA-IL2 PET measurements with radiologic response to treatment, according to (i)RECIST v1.1 criteria. Response to therapy will be assessed according to the RECIST or iRECIST guidelines. These results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images. 2 years
Secondary Assessment of changes in tumour and normal organ tracer uptake after 2 weeks of treatment, expressed as standardized uptake values. Patients will undergo a PET scan at baseline and another one during treatment. tracer uptake will be quantified and expressed as standardized uptake value (SUV) in defined volumes of interest (VOIs) for both scans. The results of both PET scans will be compared to assess changes in imaging tracer uptake over time. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT05071183 - A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05530200 - PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Phase 2
Active, not recruiting NCT04447651 - Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Recruiting NCT04419532 - A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04137900 - Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Phase 1
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT05867121 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03964727 - Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors Phase 2
Recruiting NCT06108050 - JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Completed NCT04914117 - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Phase 1
Completed NCT00997529 - Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors N/A
Recruiting NCT04614740 - The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06163391 - A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT06415487 - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Phase 1
Recruiting NCT05824975 - A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors Phase 1/Phase 2